Valneva (VALN) to Release Quarterly Earnings on Wednesday

Valneva (NASDAQ:VALN - Get Free Report) will likely be posting its Q1 2025 quarterly earnings results before the market opens on Wednesday, May 7th. Analysts expect the company to announce earnings of ($0.40) per share and revenue of $41.80 million for the quarter.

Valneva (NASDAQ:VALN - Get Free Report) last announced its earnings results on Thursday, March 20th. The company reported ($0.54) earnings per share for the quarter, missing the consensus estimate of ($0.22) by ($0.32). Valneva had a negative net margin of 4.35% and a negative return on equity of 3.93%. The business had revenue of $56.48 million for the quarter, compared to the consensus estimate of $55.64 million. On average, analysts expect Valneva to post $0 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Valneva Stock Performance

Shares of NASDAQ:VALN traded up $0.19 on Friday, hitting $6.57. The company's stock had a trading volume of 60,571 shares, compared to its average volume of 36,552. Valneva has a 12 month low of $3.62 and a 12 month high of $9.50. The stock's 50-day moving average is $6.82 and its two-hundred day moving average is $5.72. The company has a debt-to-equity ratio of 0.70, a quick ratio of 2.25 and a current ratio of 2.78. The company has a market capitalization of $549.49 million, a price-to-earnings ratio of -50.54 and a beta of 1.85.

Wall Street Analyst Weigh In

Several equities analysts have commented on the stock. HC Wainwright reissued a "buy" rating and set a $17.00 target price on shares of Valneva in a research note on Tuesday, April 15th. Guggenheim lowered their price objective on shares of Valneva from $17.00 to $15.00 and set a "buy" rating on the stock in a research note on Monday, March 24th.

Valneva Company Profile

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.